03.01.2013
- Rare diseases are a growing focus for drug companies, with prices for some treatments for ultra-rare conditions running into hundreds of thousands of dollars a year. The following...
04.04.2011
- French drugmaker Sanofi-Aventis completed its improved $20.1 billion offer for Genzyme allowing it to begin merging the U.S. biotech into its business and add rare diseases to its...
30.03.2011
- Certificates related to Sanofi-Aventis's $20.1 billion acquisition of U.S. biotech firm Genzyme could begin trading on Nasdaq as soon as April 4, depending on the outcome of its...
25.11.2010
- Genzyme Corp has met the first in a series of deadlines imposed by U.S. regulators for fixing problems at its Boston plant, a milestone that could bolster the biotech company's...
